Non-Hormonal Hot Flash Drugs: What the Trials Actually Showed

What the evidence supports#

Fezolinetant, sold as Veozah, is the first FDA-approved NK3-receptor antagonist for moderate-to-severe hot flashes of menopause, and its trial record supports a benefit that is genuine, statistically clear, and modest in size. In the phase 3 SKYLIGHT program, women on the approved 45 mg dose averaged roughly two to three fewer moderate-to-severe hot flashes per day than women on placebo, starting from about ten or more episodes a day. That result earned approval in May 2023, and it now sits alongside a boxed warning for rare but serious liver injury. The practical question is not whether the drug works, but how a given person weighs a small non-hormonal benefit against a monitoring burden and a low-probability harm.

Key points#

• Fezolinetant targets brain temperature signaling, not estrogen, giving a non-hormonal option to women who cannot or prefer not to use hormone therapy.
• The placebo-adjusted benefit in the SKYLIGHT trials was about two to three fewer moderate-to-severe flushes per day, separating early and holding through 52 weeks.
• Hot flashes respond strongly to placebo, so the raw before-and-after drop overstates what the drug itself adds.
• A December 2024 boxed warning and expanded liver monitoring reflect a rare post-marketing case of serious liver injury.

A new lever, not a hormone#

For decades the non-hormonal shelf for hot flashes held mostly repurposed antidepressants and a few older agents, each with real limits. Fezolinetant works differently, and understanding how clarifies why its approval mattered.

Hot flashes are not simply an estrogen deficit waiting to be topped up. As estrogen falls during menopause, a small group of neurons in the hypothalamus that helps set body temperature becomes overactive, driven partly by a signaling molecule called neurokinin B. Those neurons carry the neurokinin 3 (NK3) receptor. Fezolinetant blocks that receptor, quieting the misfiring that sets off a flush. Because it pulls a temperature-regulation lever rather than a hormonal one, it opens a route for the many women who avoid hormone therapy by choice or by medical necessity.

The FDA approved the drug on May 12, 2023, calling it the first in its class for this use. The efficacy case rested on two 12-week randomized, double-blind, placebo-controlled trials, SKYLIGHT 1 and SKYLIGHT 2, which together enrolled roughly a thousand women and compared 30 mg and 45 mg once daily against placebo. Each trial continued into a longer extension, and a separate year-long study looked at safety.

Reading the numbers, not just the p-value#

The SKYLIGHT 1 results appeared in The Lancet in 2023 and the SKYLIGHT 2 results in the Journal of Clinical Endocrinology and Metabolism. Both used the same co-primary endpoints: change in the frequency and severity of moderate-to-severe vasomotor symptoms at week 4 and week 12. On each endpoint the 45 mg dose beat placebo with high statistical confidence, the separation showed up within the first week, and it persisted out to 52 weeks.

This is exactly where evidence literacy earns its keep. Statistical significance answers "is this difference likely real?" It does not answer "is this difference large?" In SKYLIGHT 2 the placebo-adjusted reduction was about 2.5 fewer moderate-to-severe episodes per day at both week 4 and week 12, with a severity gap near 0.3 on the symptom scale. Those figures cleared the pre-specified bar. For a woman having a dozen disruptive flushes a day, a couple fewer can genuinely improve her days and nights. But it is a couple fewer beyond placebo, not a couple fewer overall, and the two are easy to confuse.

Why the placebo arm deserves your first look#

That distinction carries extra weight here because hot flashes are unusually responsive to placebo. Across this field, women assigned to a dummy pill routinely report their flushes dropping by roughly a third to a half over a few weeks. This is not pretense. Expectation, closer attention, seasonal shifts, and the natural month-to-month variability of symptoms all pull the numbers down on their own.

So the raw before-and-after improvement on fezolinetant looks striking, with frequency falling by a large majority from baseline. Yet much of that fall would have happened on placebo regardless. The drug's actual contribution is the gap between the two curves, and that gap is the modest number, not the headline percentage. The habit worth building is simple: whenever you read a menopause-drug study, or a supplement advertisement borrowing the same dramatic before-and-after visuals, train your eye on the placebo arm before anything else.

The liver signal and the boxed warning#

The other half of the ledger is safety. In the trials, a small number of participants had liver enzyme elevations above three times the upper limit of normal. These were generally transient, and no case met Hy's law, the laboratory pattern that flags dangerous drug-induced liver injury. That is reassuring, though not perfectly clean, and the original label reflected it by requiring liver bloodwork before starting and periodically over the first nine months.

The picture then sharpened after launch. In December 2024 the FDA added a boxed warning, its most prominent, for rare but serious liver injury. The trigger was a post-marketing report of a patient who developed symptoms and markedly abnormal liver tests within weeks of starting the drug. The agency also expanded monitoring to cover the first and second months of use.

A boxed warning is not a recall, and it does not declare a drug unsafe for everyone. It says the risk is serious enough that prescribers and patients must actively watch for it. It is also a lesson in the limits of trials: a 12-week study of a thousand people cannot detect a one-in-many-thousands event. Rare harms often surface only once a drug reaches a much larger population, which is the whole reason post-marketing surveillance exists.

The takeaway that travels#

None of this makes fezolinetant good or bad in the abstract, and this article is educational rather than medical advice. It makes it well characterized. The trials show a real mechanism producing a modest, durable, statistically solid benefit, paired with a monitoring routine and a rare serious risk that regulators took seriously enough to headline. The useful question is not whether it works, since it does, nor whether it is dangerous, since serious harm is rare when people watch for it. The question is how a specific person values two or three fewer flushes a day against periodic blood draws and a small tail risk, weighed against her other options. That trade-off belongs to a patient and her own clinician, guided by the actual numbers rather than the marketing gloss. The broader habit reaches well past menopause: when a new drug arrives, read the effect size and the placebo arm together, and give the safety label the same scrutiny you give the efficacy claim.